JP2016515098A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515098A5
JP2016515098A5 JP2015560285A JP2015560285A JP2016515098A5 JP 2016515098 A5 JP2016515098 A5 JP 2016515098A5 JP 2015560285 A JP2015560285 A JP 2015560285A JP 2015560285 A JP2015560285 A JP 2015560285A JP 2016515098 A5 JP2016515098 A5 JP 2016515098A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
dimethyl
carbazole
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015560285A
Other languages
English (en)
Japanese (ja)
Other versions
JP6395731B2 (ja
JP2016515098A (ja
Filing date
Publication date
Priority claimed from US14/190,477 external-priority patent/US9492460B2/en
Application filed filed Critical
Publication of JP2016515098A publication Critical patent/JP2016515098A/ja
Publication of JP2016515098A5 publication Critical patent/JP2016515098A5/ja
Application granted granted Critical
Publication of JP6395731B2 publication Critical patent/JP6395731B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015560285A 2013-02-27 2014-02-27 ブロモドメイン阻害剤として有用なカルバゾール化合物 Active JP6395731B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361769996P 2013-02-27 2013-02-27
US61/769,996 2013-02-27
US14/190,477 2014-02-26
US14/190,477 US9492460B2 (en) 2013-02-27 2014-02-26 Carbazole compounds useful as bromodomain inhibitors
PCT/US2014/018820 WO2014134232A1 (en) 2013-02-27 2014-02-27 Carbazole compounds useful as bromodomain inhibitors

Publications (3)

Publication Number Publication Date
JP2016515098A JP2016515098A (ja) 2016-05-26
JP2016515098A5 true JP2016515098A5 (https=) 2017-03-30
JP6395731B2 JP6395731B2 (ja) 2018-09-26

Family

ID=50382555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015560285A Active JP6395731B2 (ja) 2013-02-27 2014-02-27 ブロモドメイン阻害剤として有用なカルバゾール化合物

Country Status (10)

Country Link
US (1) US9492460B2 (https=)
EP (1) EP2961748B1 (https=)
JP (1) JP6395731B2 (https=)
CN (1) CN105008352B (https=)
BR (1) BR112015020389A8 (https=)
CA (1) CA2902737A1 (https=)
EA (1) EA027345B1 (https=)
ES (1) ES2669189T3 (https=)
MX (1) MX2015010921A (https=)
WO (1) WO2014134232A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
CN105189488B (zh) 2013-02-27 2018-07-24 百时美施贵宝公司 用作溴区结构域抑制剂的咔唑化合物
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
EP3010918B1 (en) 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
CA2915838C (en) 2013-06-21 2023-04-18 Zenith Epigenetics Corp. Bicyclic bromodomain inhibitors
AR096837A1 (es) 2013-07-08 2016-02-03 Incyte Corp Heterociclos tricíclicos como inhibidores de proteínas bet
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
ES2857848T3 (es) * 2013-12-24 2021-09-29 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos
US9580430B2 (en) 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
EA034972B1 (ru) 2014-04-23 2020-04-13 Инсайт Корпорейшн 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet
CA2947970A1 (en) * 2014-05-08 2015-11-12 Oncoethix Gmbh Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
AU2015326910B2 (en) * 2014-10-02 2018-03-01 Glaxosmithkline Intellectual Property (No.2) Limited Compound
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
HK1246273B (en) 2014-12-01 2019-12-06 恒翼生物医药(上海)股份有限公司 Substituted pyridines as bromodomain inhibitors
EP3230277B1 (en) 2014-12-11 2019-09-18 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
HK1245247A1 (zh) 2014-12-17 2018-08-24 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
US10730870B2 (en) 2015-03-18 2020-08-04 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
EP3294736B1 (en) * 2015-05-11 2020-07-22 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US9725449B2 (en) * 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2017011371A1 (en) 2015-07-10 2017-01-19 Arvinas, Inc Mdm2-based modulators of proteolysis and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
US10550091B2 (en) 2016-03-25 2020-02-04 St. Jude Children's Research Hospital 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor
WO2017172914A1 (en) 2016-03-30 2017-10-05 Wisconsin Alumni Research Foundation Methods and compositions for modulating frataxin expression
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
KR102643344B1 (ko) 2016-06-20 2024-03-07 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
BR112019015484A2 (pt) 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
WO2018183679A1 (en) 2017-03-29 2018-10-04 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
CA3165168A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN111809182B (zh) * 2020-07-08 2025-04-18 江苏和达电子科技有限公司 一种用于铜/钼（铌）/igzo膜层的刻蚀液及其制备方法和应用
US12016847B2 (en) 2021-03-12 2024-06-25 Bristol-Myers Squibb Company Methods of treating prostate cancer
AU2023273729A1 (en) * 2022-05-20 2024-12-05 University Of Puerto Rico 1,4,5-trisubstituted-1,2,3-triazoles and uses thereof
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
US20260092058A1 (en) 2024-09-30 2026-04-02 St. Jude Children's Research Hospital, Inc. Small Molecule Degraders and Fluorescent Probes of PXR

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310635D0 (en) * 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
DE60130891T2 (de) * 2000-06-29 2008-07-17 Anthera Pharmaceuticals Inc., San Mateo Heilmittel für krebs
CA2441077A1 (en) * 2001-03-28 2002-10-10 Eli Lilly And Company Substituted carbazoles as inhibitors of spla2
US6602619B2 (en) 2001-10-19 2003-08-05 Lightronik Technology Inc. Organic EL device
CA2542682A1 (en) 2003-10-18 2005-05-06 Bayer Healthcare Ag 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
WO2006012310A2 (en) * 2004-06-25 2006-02-02 Genzyme Corporation Carbazole derivatives for treating polycystic kidney disease
US8815840B2 (en) * 2008-12-19 2014-08-26 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
ES2563057T3 (es) * 2009-11-05 2016-03-10 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
JP5623996B2 (ja) 2010-09-21 2014-11-12 株式会社半導体エネルギー研究所 カルバゾール誘導体
JP5842630B2 (ja) 2011-03-16 2016-01-13 株式会社リコー カルバゾール誘導体、及び半導体ナノ結晶
TW201302973A (zh) * 2011-05-03 2013-01-16 羅門哈斯電子材料韓國公司 新穎有機電場發光化合物及使用該化合物之有機電場發光裝置
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4

Similar Documents

Publication Publication Date Title
JP2016515098A5 (https=)
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
TWI579284B (zh) 咪唑并吡咯啶酮化合物
AU2008236562B2 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
JP2025508702A (ja) キナゾリン化合物、及び変異ｋｒａｓタンパク質の阻害剤としてのその使用
JP2024517695A (ja) 複素環式化合物及び使用方法
RU2665036C2 (ru) Гетероароматические соединения-модуляторы фосфоинозидит-3-киназы и способы применения
JP6935415B2 (ja) ２−アミノ−Ｎ−［７−メトキシ−２，３−ジヒドロイミダゾ−［１，２−ｃ］キナゾリン−５−イル］ピリミジン−５−カルボキサミド類
RU2672910C9 (ru) Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы
WO2016203404A1 (en) Compounds and compositions for inhibiting the activity of shp2
JP2017524702A5 (https=)
KR20010050223A (ko) Ｃｒｆ 길항제 및 관련 조성물의 용도
JP2023549055A (ja) 複素環式スピロ化合物及びその使用方法
JP2016537384A5 (https=)
WO2019071147A1 (en) INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
JP2016530283A5 (https=)
JP2012532131A5 (https=)
JP2016523974A5 (https=)
JP2014518544A5 (https=)
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
WO2016151499A1 (en) Formylated n-heterocyclic derivatives as fgfr4 inhibitors
JP2016509056A5 (https=)
RU2014126750A (ru) Ингибиторы тирозинкиназы брутона
RU2019108717A (ru) Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
JP2021514011A5 (https=)